Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 8/2008

01-10-2008 | Original Paper

Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study

Authors: Yung-Kai Huang, Ya-Li Huang, Yu-Mei Hsueh, Mo-Hsiung Yang, Meei-Maan Wu, Shu-Yuan Chen, Ling-I Hsu, Chien-Jen Chen

Published in: Cancer Causes & Control | Issue 8/2008

Login to get access

Abstract

The risk of urothelial carcinoma (UC) and urinary arsenic speciation have been evaluated in a few case–control studies; however, the association has not been verified in a prospective cohort study. The aim of this study was to examine the association between urinary arsenic speciation and the incidence of UC in a cohort study. A total of 1,078 residents of southwestern Taiwan were followed for an average of 12 years. A high-performance liquid chromatography/hydride generator and an atomic absorption spectrometry were used to measure urinary arsenite, arsenate, monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV). The incidence of UC was estimated by examining the National Cancer Registry of Taiwan between January 1985 and December 2001. There were 37 newly diagnosed cases of UC during a follow-up period of 11,655 person-years. Significantly higher percentages of MMAV and lower percentages of DMAV existed among the patients with UC than among the healthy residents. After adjustment for age, gender, educational level, and smoking status, the percentage of urinary DMAV was shown to have an inverse association with the risk of UC, having a relative risk (RR) of the tertile strata of 1.0, 0.3, and 0.3, respectively (p < 0.05 for the trend test). The RR (95% confidence interval) of residents with a cumulative arsenic exposure (CAE) of ≥20 mg/l-year and a higher percentage of MMAV or a CAE of ≥20 mg/l-year and a lower percentage of DMAV was 3.7 (1.2–11.6) or 4.2 (1.3–13.4) compared to residents with a CAE of <20 mg/l-year and a lower percentage of MMAV or a CAE of <20 mg/l-year and a higher percentage of DMAV respectively. There was a significant association between inefficient arsenic methylation and the development of UC in the residents in the high CAE exposure strata in an area of southwestern Taiwan endemic for arseniasis.
Literature
1.
IARC (1980) Some metals and metallic compounds. International Agency for Research on Cancer, Lyon, Franch, p 325
2.
Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895–5899PubMed
3.
Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892PubMed
4.
Chiou HY, Hsueh YM, Liaw KF et al (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296–1300PubMed
5.
National Research Council (2001) Arsenic in drinking water: 2001 update. National Academy Press, Washington, DC
6.
Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res -Rev Mutat Res 612:215–246
7.
Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660–669PubMed
8.
Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99:920–928PubMedCrossRef
9.
HopenhaynRich C, Biggs ML, Fuchs A et al (1996) Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117–124CrossRef
10.
Vahter M (1981) Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats. Environ Res 25:286–293PubMedCrossRef
11.
12.
Buchet JP, Lauwerys R, Roels H (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48:71–79PubMedCrossRef
13.
Buchet JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111–118PubMedCrossRef
14.
Vahter M (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Progr 82:69–88
15.
Styblo M, Del Razo LM, Vega L et al (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289–299PubMedCrossRef
16.
Petrick JS, Jagadish B, Mash EA, Aposhian HV (2001) Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14:651–656PubMedCrossRef
17.
Nesnow S, Roop BC, Lambert G et al (2002) DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 15:1627–1634PubMedCrossRef
18.
Chen YC, Su HJ, Guo YL et al (2003) Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310PubMedCrossRef
19.
Chen YC, Guo YL, Su HJ et al (2003) Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248PubMedCrossRef
20.
Hsueh YM, Chiou HY, Huang YL et al (1997) Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589–596PubMed
21.
Yu RC, Hsu KH, Chen CJ, Froines JR (2000) Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262PubMed
22.
Pu YS, Yang SM, Huang YK et al (2007) Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99–106PubMedCrossRef
23.
Steinmaus C, Bates MN, Yuan Y et al (2006) Arsenic methylation and bladder cancer risk in case–control studies in Argentina and the United States. J Occup Environ Med 48:478–488PubMedCrossRef
24.
Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intra individual variability in Arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
25.
26.
Hughes MF (2006) Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect 114:1790–1796PubMed
27.
Wu HY, Chen KP, Tseng WP, Hsu CL (1961) Epidemiologic studies on blackfoot disease: I. Prevalence and incidence of the disease by age, sex, occupation and geographical distribution. Mem College Med Natl Taiwan Univ 7:33–50
28.
Chen CJ, Hsueh YM, Lai MS et al (1995) Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53–60PubMed
29.
Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32:S66–S81PubMedCrossRef
30.
US Department of Health, Human Services (2001) International classification of diseases, ninth revision, clinical modification. US Public Health Service, Washington, DC
31.
SEER Program NCI (2001) Conversion of morphology of ICD-O-2 to ICD-O-3. In: Percy C, Fritz A, Ries L (eds) National Cancer Institute, Bethedsa, pp 1–160
32.
Hsueh YM, Huang YL, Huang CC et al (1998) Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 54:431–444PubMedCrossRef
33.
Kuo TL (1964) Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7–13
34.
Lo MC, Hsen YC, Lin BK (1977) Arsenic content of underground water in Taiwan: second report. Taiwan Provincial Institute of Environmental Sanitation, Taichung
35.
Breslow NE, Day NE (1987) Statistical methods in cancer research. vol 2. The analysis of cohort studies. International Agency for Research on Cancer, Lyon, p 120
36.
Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
37.
Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE (1996) Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620–628PubMedCrossRef
38.
Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ (2002) Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83–91PubMedCrossRef
39.
Concha G, Nermell B, Vahter MV (1998) Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ Health Perspect 106:355–359PubMedCrossRef
40.
Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT (1995) A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455–462PubMedCrossRef
41.
Chiou HY, Hsueh YM, Hsieh LL et al (1997) Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res -Rev Mutat Res 386:197–207
42.
Marnell LL, Garcia-Vargas GG, Chowdhury UK et al (2003) Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507–1513PubMedCrossRef
43.
Schmuck EM, Board PG, Whitbread AK et al (2005) Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics 15:493–501PubMedCrossRef
44.
Wood TC, Salavaggione OE, Mukherjee B et al (2006) Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364–7373PubMedCrossRef
45.
Francesconi KA, Kuehnelt D (2004) Determination of arsenic species: a critical review of methods and applications, 2000–2003. Analyst 129:373–395PubMedCrossRef
46.
Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127–144PubMedCrossRef
47.
Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225–232PubMedCrossRef
48.
Drobna Z, Jaspers I, Thomas DJ, Styblo M (2003) Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17:67–69PubMed
49.
Gong ZL, Lu XF, Cullen WR, Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrum 16:1409–1413CrossRef
50.
Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282–293PubMedCrossRef
51.
Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG et al (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250–254PubMedCrossRef
52.
Le XC, Cullen WR, Reimer KJ (1994) Human urinary arsenic excretion after one-time ingestion of seaweed, crab, and shrimp. Clin Chem 40:617–624PubMed
53.
Ma M, Le XC (1998) Effect of arsenosugar ingestion on urinary arsenic speciation. Clin Chem 44:539–550PubMed
54.
Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
Metadata
Title
Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study
Authors
Yung-Kai Huang
Ya-Li Huang
Yu-Mei Hsueh
Mo-Hsiung Yang
Meei-Maan Wu
Shu-Yuan Chen
Ling-I Hsu
Chien-Jen Chen
Publication date
01-10-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 8/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9146-5

Other articles of this Issue 8/2008

Cancer Causes & Control 8/2008 Go to the issue

Original Paper

Flavonoid intake and liver cancer: a case–control study in Greece

Original Paper

Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case–control study in Hawaii

Original Paper

Lymphoma survival patterns by WHO subtype in the United States, 1973–2003

Original Paper

History of benign breast disease and risk of breast cancer among women in China: a case–control study

Original Paper

Unpasteurized milk consumption and subsequent risk of cancer

Original Paper

Deaths from non-melanoma skin cancer in Western Australia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits